Corporate Snapshot – Vaxart (NASDAQ: VXRT)
Vaxart’s stock slipped 2.17 % in the 24 hours leading up to 09:55 PM CET on Thursday, 22 Oct 2026, trading at roughly USD 0.44. With a market cap of USD 119.2 million and an outstanding supply of 243.2 million shares, the company has seen a 10 % decline since the end of last month. The 200‑day simple moving average sits at USD 0.59, while the all‑time high for the last 52 weeks was USD 0.84 on 1 Dec 2026 and the low was USD 0.31 on 11 Apr 2025.
Recent Filings – Director Ownership Moves
On 16 Oct 2026, Vaxart filed a Form 3 confirming that Director Raquel C. Bono owns common stock under a vesting schedule tied to her board service. A Form 4 filed on 20 Oct 2026 documents Bono’s exercise of stock‑option rights, adding about 157 000 shares to her holdings. That same day the company submitted a limited power of attorney, enabling designated attorneys to manage SEC reporting obligations on Bono’s behalf. These filings illustrate a strategic tightening of ownership alignment between senior leadership and shareholder value.
24‑Hour Peer Performance
| Ticker | % Change | Price | Market Cap | Notable Developments |
|---|---|---|---|---|
| LEE (Lee) | +2.18 % | USD 6.46 | USD 142.9 m | Stable growth trajectory |
| GOW (Gowell Energy) | –10.89 % | USD 3.41 | USD 141.2 m | Strong first‑half revenue surge (43 %) and operating profit jump (135 %). Projected 2026 revenue $60‑$68 m, Adjusted EBITDA $25‑$29 m. |
| TLYS (Tilly’s) | –0.65 % | USD 4.43 | USD 141.6 m | P/E of 78.51 indicates valuation pressure |
| DFDV (Defi Development) | +12.66 % | USD 3.78 | USD 142.2 m | Two directors resigned; filed free‑writing prospectus for Variable Rate Series C Perpetual Preferred Stock |
| HSDT (Solana) | +1.29 % | USD 2.27 | USD 140.9 m | Minor upside on broader market |
Forward‑Looking Outlook
Vaxart’s focus on oral flu vaccines positions it within a niche yet expanding segment of the biopharma market. The company’s technology—stimulating gut‑associated lymphoid tissue—offers a dual systemic and mucosal immune response, potentially differentiating it from conventional injectable vaccines. While recent stock performance has been modest, the strategic alignment of board ownership and the company’s clear product pipeline suggest a stable foundation for future upside. Investors should monitor upcoming clinical milestones and any regulatory approvals that could act as catalysts for a renewed rally.
